<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Midregional Proenkephalin A (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>-PENK A) and N-terminal Protachykinin A (NT-<z:mp ids='MP_0002633'>PTA</z:mp>) are stable fragments of the precursor <z:chebi fb="7" ids="16670">peptides</z:chebi> for enkephalins and substance P, respectively </plain></SENT>
<SENT sid="1" pm="."><plain>We measured <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>-PENK A and NT-<z:mp ids='MP_0002633'>PTA</z:mp> concentrations by sensitive chemiluminescence immunoassays in cerebrospinal fluid (CSF) of 19 neurologically healthy controls (<z:chebi fb="1" ids="51369">NHC</z:chebi>), 28 patients with other <z:e sem="disease" ids="C0027765" disease_type="Disease or Syndrome" abbrv="">neurologic disorders</z:e> (OND), 70 patients with <z:hpo ids='HP_0000726'>dementia</z:hpo> disorders (38 Alzheimer's disease [AD], 8 <z:hpo ids='HP_0000726'>dementia</z:hpo> with <z:hpo ids='HP_0100315'>Lewy bodies</z:hpo> [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e>], 12 <z:hpo ids='HP_0002145'>frontotemporal dementia</z:hpo> [FTD], and 12 patients with vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> [VD]), and 16 patients with <z:hpo ids='HP_0011009'>acute</z:hpo> neuroinflammation (AN) </plain></SENT>
<SENT sid="2" pm="."><plain>Median concentrations of NT-<z:mp ids='MP_0002633'>PTA</z:mp> were decreased in <z:hpo ids='HP_0000001'>all</z:hpo> patient groups compared to <z:chebi fb="1" ids="51369">NHC</z:chebi> showing significant differences between patients with <z:chebi fb="1" ids="51369">NHC</z:chebi> and AN (p&lt;0.001), OND and AN (p&lt;0.001), FTD and AN (p&lt;0.01) and pAD and AN (p&lt;0.05) </plain></SENT>
<SENT sid="3" pm="."><plain>Median <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>-PENK A levels were lower in patients with OND, <z:hpo ids='HP_0000726'>dementia</z:hpo> disorders (including AD, FTD, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e> and VD) and AN compared to <z:chebi fb="1" ids="51369">NHC</z:chebi> subjects, although this differences did not reach statistical significance (p&gt;0.05) </plain></SENT>
<SENT sid="4" pm="."><plain>A maximum difference of both proneuropeptide fragments was found between <z:chebi fb="1" ids="51369">NHC</z:chebi> subjects and patients with AN, with a more than 2fold decrease in median NT-<z:mp ids='MP_0002633'>PTA</z:mp> and a 1.5fold decrease in median <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>-PENK A levels </plain></SENT>
<SENT sid="5" pm="."><plain>Concentrations of both proneuropeptide fragments were positively correlated in <z:hpo ids='HP_0000001'>all</z:hpo> patients (r=0.77, p&lt;0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>Our results indicate alterations of the cerebral PENK A- and <z:mp ids='MP_0002633'>PTA</z:mp>-system in both, <z:hpo ids='HP_0000726'>dementia</z:hpo> and <z:hpo ids='HP_0011009'>acute</z:hpo> neuroinflammatory disorders </plain></SENT>
<SENT sid="7" pm="."><plain>These neuropeptide systems seem to be highly correlated in healthy and pathological status </plain></SENT>
</text></document>